echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Lancet Haematol: Early recognition of vascular endothelial cell lesions and reducing their progression may improve the outcome of COVID-19 patients

    Lancet Haematol: Early recognition of vascular endothelial cell lesions and reducing their progression may improve the outcome of COVID-19 patients

    • Last Update: 2021-05-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    2 An important feature of the pathogenesis of coronavirus of severe acute respiratory syndrome is COVID-19 associated coagulopathy, which is characterized by thrombotic and micro- vascular complications increase.


    COVID-19 thrombus blood vessel

    In this single-center cross-sectional study, the researchers included hospitalized adult (≥18 years) patients with COVID-19, and recruited asymptomatic, non-hospitalized participants as the control group.


     

    From April 13 to April 24, 2020, a total of 68 COVID-19 patients were included in the study, including 48 ICU and 20 non-ICU patients, as well as 13 non-hospitalized, asymptomatic control groups.


    In summary, the research results show that patients with COVID-19 have endothelial cell pathology, and endothelial cell pathology may be related to critical illness and death.


     

    Original source:

     

    George Goshua, et al.


    ncbi.
    nlm.
    nih.
    gov/32619411/" target="_blank" rel="noopener">Endotheliopathy in COVID-19-associated coagulopathy : evidence from a single-centre, cross-sectional study in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.